Jain Rita — SEC insider filings
SEC reporting owner CIK 1707797. 34 insider filings on record with FilingPulse; latest filed 2026-10-02.
Transaction summary — filings shown
Covers all 34 filings on record, filed 2021-01-25 to 2026-10-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 73.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ChemoCentryx, Inc. (CCXI) | EVP, Chief Medical Officer, Director | 7 | — | — | 21 |
| ANAPTYSBIO, INC (ANAB) | Director | 6 | — | — | 16 |
| First Tracks Biotherapeutics, Inc. (TRAX) | Director | 4 | — | — | 15 |
| Avalo Therapeutics, Inc. (AVTX) | Director | 7 | — | — | 7 |
| Immunovant, Inc. (IMVT) | Chief Medical Officer | 3 | — | — | 7 |
| Celldex Therapeutics, Inc. (CLDX) | Director | 4 | — | — | 4 |
| Provention Bio, Inc. (PRVB) | Director | 2 | — | — | 2 |
| SAB Biotherapeutics, Inc. (SABS) | Director | 1 | — | — | 1 |
Insider filings — Jain Rita
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-10-02 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 1,322 (derivative) @ $12.29 | EDGAR |
| 2026-07-02 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 1,080 (derivative) @ $15.04 | EDGAR |
| 2026-06-29 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2026-06-17 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Option exercise (M): 7,330 @ $0 · Option exercise (M): 6,030 (derivative) @ $0 · Option exercise (M): 1,300 (derivative) @ $0 | EDGAR |
| 2026-06-12 | 4/A | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 2,500 (derivative) @ $0 · Grant/award (A): 7,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 20,100 (derivative) @ $0 | EDGAR |
| 2026-05-14 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-04-22 | 4 | First Tracks Biotherapeutics, Inc. (TRAX) | Grant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 8,015 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 1,300 (derivative) @ $0 · +2 more | EDGAR |
| 2026-04-01 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 1,339 (derivative) @ $12.13 | EDGAR |
| 2026-01-08 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 5,500 (derivative) @ $0 · Grant/award (A): 4,000 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | SAB Biotherapeutics, Inc. (SABS) | Grant/award (A): 240,000 (derivative) @ $0 | EDGAR |
| 2026-01-05 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 1,043 (derivative) @ $14.74 | EDGAR |
| 2025-10-02 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 1,572 (derivative) @ $0 | EDGAR |
| 2025-06-18 | 4 | Avalo Therapeutics, Inc. (AVTX) | Grant/award (A): 40,200 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 7,330 @ $0 · Option exercise (M): 1,300 (derivative) @ $0 · Option exercise (M): 6,030 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2025-01-07 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 6,030 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | ANAPTYSBIO, INC (ANAB) | Option exercise (M): 4,534 @ $0 · Option exercise (M): 3,234 (derivative) @ $0 · Option exercise (M): 1,300 (derivative) @ $0 | EDGAR |
| 2024-06-17 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 16,500 (derivative) @ $0 | EDGAR |
| 2024-01-05 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 16,510 (derivative) @ $0 · Grant/award (A): 6,030 (derivative) @ $0 | EDGAR |
| 2023-04-27 | 4 | Provention Bio, Inc. (PRVB) | Disposition to issuer (D): 66,000 (derivative) | EDGAR |
| 2023-04-06 | 4 | ANAPTYSBIO, INC (ANAB) | Grant/award (A): 10,600 (derivative) @ $0 · Grant/award (A): 8,015 (derivative) @ $0 · Grant/award (A): 3,900 (derivative) @ $0 · Grant/award (A): 3,234 (derivative) @ $0 | EDGAR |
| 2023-02-21 | 4 | Celldex Therapeutics, Inc. (CLDX) | Grant/award (A): 17,100 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | Provention Bio, Inc. (PRVB) | Grant/award (A): 66,000 (derivative) @ $0 | EDGAR |
| 2022-10-24 | 4 | ChemoCentryx, Inc. (CCXI) | Disposition to issuer (D): 35,863 · Disposition to issuer (D): 307 (derivative) · Disposition to issuer (D): 14,393 (derivative) · Disposition to issuer (D): 21,052 (derivative) · Disposition to issuer (D): 23,948 (derivative) · Disposition to issuer (D): 4,504 (derivative) · +2 more | EDGAR |
| 2022-05-24 | 4 | ChemoCentryx, Inc. (CCXI) | Option exercise (M): 7,726 @ $0 · Option exercise (M): 7,726 (derivative) | EDGAR |
| 2022-03-29 | 4 | ChemoCentryx, Inc. (CCXI) | Option exercise (M): 5,251 @ $0 · Option exercise (M): 5,251 (derivative) | EDGAR |
| 2022-02-24 | 4 | ChemoCentryx, Inc. (CCXI) | Grant/award (A): 11,600 (derivative) · Grant/award (A): 14,700 (derivative) | EDGAR |
| 2021-10-07 | 4 | ChemoCentryx, Inc. (CCXI) | Grant/award (A): 45,000 (derivative) | EDGAR |
| 2021-05-24 | 4 | ChemoCentryx, Inc. (CCXI) | Option exercise (M): 4,660 @ $0 · Grant/award (A): 7,726 (derivative) · Grant/award (A): 4,504 (derivative) · Option exercise (M): 4,660 (derivative) | EDGAR |
| 2021-03-31 | 4/A | Immunovant, Inc. (IMVT) | Grant/award (A): 97,600 @ $0 · Grant/award (A): 11,765 @ $0 · Grant/award (A): 342,300 (derivative) @ $0 | EDGAR |
| 2021-03-30 | 4 | ChemoCentryx, Inc. (CCXI) | Option exercise (M): 5,251 @ $0 · Option exercise (M): 5,251 (derivative) | EDGAR |
| 2021-03-23 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 109,365 @ $0 · Grant/award (A): 342,300 (derivative) @ $0 | EDGAR |
| 2021-01-25 | 4 | Immunovant, Inc. (IMVT) | Grant/award (A): 20,000 @ $0 · Grant/award (A): 220,000 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2021-01-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1707797 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs